Our results suggest that the synergistic antitumor effects of dasatinib/gemcitabine combination are mediated by reducing the level of ALDH1A1 in ALDH1A1-enriched pancreatic cancer MIA PaCa-2 cells. Here, ALDH1A1 is linked to pancreatic neoplasm.